AstraZeneca’s COVID Vaccine Trials Resumed in United States with FDA’s Approval

Sharing is caring!

While the fight with COVID 19 holds a great level of relevance for everyone. It is important to keep an eye on pharma companies who are working on bringing out the vaccine to overcome this global pandemic. As a matter of a positive development in this front, clinical trials for the AstraZeneca Oxford coronavirus vaccine — AZD1222 — have resumed in the United States after approval by the Food and Drug Administration (FDA), the company said.

According to an official statement issued by AstraZeneca, “The FDA has authorised the restart in the US, following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial.”

“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so,” the statement added.

AstraZeneca’s US trial was paused since September 6 after the UK-based biopharma giant had announced that the phase 3 testing of its COVID-19 vaccine has been put on hold due to a suspected serious adverse reaction in a participant in the United Kingdom.

The trials of the third phase of AstraZeneca’s coronavirus vaccine had resumed in the UK in September.

The company said in its statement, “It is not unusual that in large scale vaccine trials, some participants will become unwell, and every case has to be evaluated to ensure the careful assessment of safety.”

AstraZeneca is working with the UK’s University of Oxford to develop the coronavirus vaccine, one of four that started late-stage, Phase 3 trials in the US.

According to the latest update by Johns Hopkins University, globally 42,020,333 people have tested positive for coronavirus and 1,140,953 deaths have been reported so far.

SMEStreet Edit Desk

SMEStreet Edit Desk is a small group of excited and motivated journalists and editors who are committed to building MSME ecosystem through valuable information and knowledge spread.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
%d bloggers like this: